NCT04728061View on ClinicalTrials.gov

Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of GEn1E-1124

PHASE1CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

January 7, 2021

Primary Completion Date

June 18, 2021

Study Completion Date

June 18, 2021

Conditions

Healthy

Interventions

DRUG

Gen1E-1124

Intravenously-infused Gen1E-1124 in vehicle.

DRUG

Placebo

Intravenously-infused vehicle.

Trial Locations (1)

8011

GEn1E-1124 Clinical Research Site, Christchurch

Sponsors

Lead Sponsor

GEn1E Lifesciences

All Listed Sponsors

lead

GEn1E Lifesciences

INDUSTRY